Companies
Howden
published a 2026 report on how insurance can support the UK pharmaceutical and life-sciences sector through its current transition, reflecting an active dedicated life-sciences broking practice.
- Country
- United Kingdom
EU
Coverage
| EU | US | |
|---|---|---|
| insurance-risk | ✓ | ✓ |
Regulatorsfdaema
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | £4.5 billion equity finance raised by the UK life sciences sector in 2024 (2024-01-01) | gov.uk |
| Capacity | 51,800 square metres for advanced therapies manufacturing capacity in 2024 (2024-01-01) | abpi.org.uk |
| Headcount | 48,100 people employed in UK pharmaceutical manufacturing in 2022 (2022-01-01) | gov.uk |
| Revenue | £24.4 billion market size of the UK pharmaceutical preparations manufacturing industry in 2026 (2026-01-01) | img2.ibisworld.com |
| Production site | 26 dedicated UK cell and gene therapy manufacturers in 2023 (2023-01-01) | icaew.com |
Independent sources: abpi.org.uk · gov.uk · icaew.com · img2.ibisworld.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Clinical-trial insurance brokerage | insurance-risk | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.